NASDAQ:ENVB

Enveric Biosciences (ENVB) Stock Forecast, Price & News

Notice: Trading of Enveric Biosciences halted at 09:37 AM EST due to "LULD pause".

$3.59

+2.07 (+136.18%)

(As of 05/18/2023 ET)

Compare

Today's Range: $2.02
▼
$4.49
50-Day Range: $1.33
▼
$2.06
52-Week Range: $1.30
▼
$18.50

Volume: 119.39 million shs
Average Volume: 1.30 million shs
Market Capitalization: $7.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $43.75

Enveric Biosciences MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,118.7% Upside
$43.75 Price Target
Short Interest: Healthy
1.75% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.21
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Enveric Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $43.75, Enveric Biosciences has a forecasted upside of 1,118.7% from its current price of $3.59.
Amount of Analyst Coverage
Enveric Biosciences has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.75% of the float of Enveric Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Enveric Biosciences has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Enveric Biosciences has recently increased by 44.44%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Enveric Biosciences does not currently pay a dividend.
Dividend Growth
Enveric Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ENVB.

2.3

News and Social Media Coverage

News Sentiment
Enveric Biosciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Enveric Biosciences this week, compared to 0 articles on an average week.
Search Interest
7 people have searched for ENVB on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Enveric Biosciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.97% of the stock of Enveric Biosciences is held by insiders.
Percentage Held by Institutions
Only 13.40% of the stock of Enveric Biosciences is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Enveric Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Enveric Biosciences is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Enveric Biosciences has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Enveric Biosciences (NASDAQ:ENVB) Stock

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. It is a patient-centric biotechnology company endeavouring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. The firm is testing natural compounds, starting with cannabinoids to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs. The company is headquartered in Naples, FL.

Receive ENVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENVB Stock News Headlines

May 18, 2023 | msn.com

Enveric Bio Stock Spikes 115% After Its Novel Prodrug Of Psilocin Receives Notice Of Allowance From US Patent And Trademark Office

May 18, 2023 | theglobeandmail.com

Enveric Biosciences (NASDAQ: ENVB) Obtains Notice of Allowance For a U.S. Patent Covering Its Innovative Psilocin Prodrug, EB-373

May 18, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

May 18, 2023 | msn.com

Enveric Skyrockets on Bagging Notice of Allowance from USPTO for Lead Candidate

May 18, 2023 | finance.yahoo.com

Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

May 15, 2023 | msn.com

Enveric Biosciences Q1 Net Loss Of $4.80M, More On Basic And Diluted Loss Per Share

April 14, 2023 | markets.businessinsider.com

EXCLUSIVE: Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'

April 10, 2023 | finance.yahoo.com

Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

May 18, 2023 | Tradewins (Ad)

The Easiest Way To Start Trading Options

Trading and options expert Chuck Hughes’ new guide reveals the simplest way to begin profitable options trading, even if you have zero experience. And if you download this free guide today, you will also receive a special bonus from Hughes himself.

April 3, 2023 | finance.yahoo.com

Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

March 28, 2023 | americanbankingnews.com

Enveric Biosciences (ENVB) Set to Announce Earnings on Wednesday

March 23, 2023 | finance.yahoo.com

Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

March 21, 2023 | finance.yahoo.com

Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

March 14, 2023 | benzinga.com

Enveric Biosciences: Novel Next-Gen Drug Discovery Platform Includes Rare Toad Enzyme

February 28, 2023 | finance.yahoo.com

Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 23, 2023 | finance.yahoo.com

Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 22, 2023 | seekingalpha.com

ENVB Enveric Biosciences, Inc.

February 22, 2023 | finance.yahoo.com

Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

February 1, 2023 | finance.yahoo.com

Enveric Biosciences to Present at the BIO CEO & Investor Conference

December 21, 2022 | finance.yahoo.com

Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

November 16, 2022 | finance.yahoo.com

Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

November 1, 2022 | finance.yahoo.com

Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022

October 24, 2022 | finance.yahoo.com

Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

October 12, 2022 | finance.yahoo.com

Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

August 31, 2022 | finance.yahoo.com

Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

August 10, 2022 | finanznachrichten.de

Microsmallcap.com: Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

July 27, 2022 | uk.investing.com

Enveric Biosciences Stock Is Nosediving Today: What's Happening?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ENVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENVB Company Calendar

Today: 5/18/2023
Next Earnings (Estimated): 8/11/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ENVB
CUSIP: N/A
CIK: 890821
Web: jaypharma.co
Phone: (239) 302-1707
Fax: 732-243-9254
Employees: 2
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $43.75
High Stock Price Forecast: $62.50
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +1,293.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($11.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,470,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -64.14%
Return on Assets: -47.27%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.34
Quick Ratio: 4.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.01 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 2,080,000
Free Float: 1,975,000
Market Cap: $6.53 million
Optionable: Not Optionable
Beta: 1.47

Key Executives

Joseph Tucker
Chief Executive Officer & Director

Avani V. Kanubaddi
President & Chief Operating Officer

Kevin M Coveney
Chief Financial Officer

Jillian Hagel
Chief Technology Officer

Bob Dagher
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

AdvisorShares Investments LLC
Bought 26,721 shares on 5/9/2023
Ownership: 6.876%

View All Institutional Transactions

ENVB Stock - Frequently Asked Questions

Should I buy or sell Enveric Biosciences stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enveric Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENVB shares.
View ENVB analyst ratings or view top-rated stocks.
What is Enveric Biosciences' stock price forecast for 2023?: 1 equities research analysts have issued 1 year price targets for Enveric Biosciences' shares. Their ENVB share price forecasts range from $25.00 to $62.50. On average, they anticipate the company's stock price to reach $43.75 in the next year. This suggests a possible upside of 1,293.3% from the stock's current price.
View analysts price targets for ENVB or view top-rated stocks among Wall Street analysts.
How have ENVB shares performed in 2023?: Enveric Biosciences' stock was trading at $2.08 on January 1st, 2023. Since then, ENVB shares have increased by 51.0% and is now trading at $3.14.
View the best growth stocks for 2023 here.
Are investors shorting Enveric Biosciences?: Enveric Biosciences saw a increase in short interest in April. As of April 30th, there was short interest totaling 32,500 shares, an increase of 44.4% from the April 15th total of 22,500 shares. Based on an average daily trading volume, of 32,200 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.8% of the shares of the company are sold short.
View Enveric Biosciences' Short Interest.
When is Enveric Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our ENVB earnings forecast.
What ETF holds Enveric Biosciences' stock ?: AdvisorShares Psychedelics ETF holds 122,429 shares of ENVB stock, representing 2.69% of its portfolio.

When did Enveric Biosciences' stock split?: Shares of Enveric Biosciences reverse split on the morning of Friday, July 15th 2022. The 1-50 reverse split was announced on Friday, July 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.
What is Enveric Biosciences' stock symbol?: Enveric Biosciences trades on the NASDAQ under the ticker symbol "ENVB."
Who are Enveric Biosciences' major shareholders?: Enveric Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (6.88%).
How do I buy shares of Enveric Biosciences?: Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Enveric Biosciences' stock price today?: One share of ENVB stock can currently be purchased for approximately $3.14.
How much money does Enveric Biosciences make?: Enveric Biosciences (NASDAQ:ENVB) has a market capitalization of $6.53 million. The company earns $-18,470,000.00 in net income (profit) each year or ($11.39) on an earnings per share basis.
How can I contact Enveric Biosciences?: Enveric Biosciences' mailing address is 4080 MCGINNIS FERRY ROAD SUITE 1306, ALPHARETTA GA, 30005. The official website for the company is jaypharma.co. The company can be reached via phone at (239) 302-1707, via email at ir@ameri100.com, or via fax at 732-243-9254.

This page (NASDAQ:ENVB) was last updated on 5/18/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Enveric Biosciences (ENVB) Stock Forecast, Price & News

Enveric Biosciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Enveric Biosciences (NASDAQ:ENVB) Stock

ENVB Stock News Headlines

ENVB Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

ENVB Stock - Frequently Asked Questions

Overall MarketRank^™